Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.57 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6686729 | 0.90 | NTRK1 (0.58) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7222018 | 0.86 | GABRA1 (0.59) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL8150 | 0.85 | GABRA2 (0.70) | GABRB2SLC2A1SLC2A2 | |
| SCHEMBL1431027 | 0.85 | KDM4E (0.59) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL1691661 | 0.85 | KDM4E (0.69) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL1430614 | 0.83 | SLC2A2 (0.77) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL1431043 | 0.82 | KDM4E (0.69) | KDM4ENPC1POLBHTTRAB9A | |
| Hydrochloric Acid SCHEMBL1430093 | 0.82 | KDM4E (0.69) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL13341895 | 0.82 | NPC1 (0.56) | KDM4ENPC1POLBHTTRAB9A | |
| SCHEMBL28391511 | 0.81 | GABRA2 (0.48) | GABRB2SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084806-A1 | Processes for the preparation of imidazo[1,2-a] pyridine derivatives | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2006-04-20 | — | — | US | disclosed |
| US-4460592-A | HYPNOTIC | SYNTHELABO | 1984-07-17 | — | — | US | disclosed |
| US-4382938-A | HYPNOSIS; TENSION; ANTICONVULSANTS; PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | SYNTHELABO (FR) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084806-A1 | Processes for the preparation of imidazo[1,2-a] pyridine derivatives | CBR1, HNRNPA2B1, HNRNPR | KDM4E 3801/4885NPC1 1312/4885POLB 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.